Hamlet BioPharma (HAMLET) Q1 26/27 earnings summary

Executive summary

• Phase III clinical treatment of patients with non-muscle invasive bladder cancer began in September at Motol Hospital in Prague; Alpha1H was produced to Phase III quality and shipped to the site.

• Development advanced across cancer and anti-infectives; three Phase II studies have been completed on a reported budget of less than SEK 300 million.

• Commercialization discussions for Alpha1H in bladder cancer continued with a leading German pharmaceutical company, with potential co-development and market access dependent on Phase III results and approval.

Financial highlights

• Q1 net sales were KSEK 0 versus KSEK 0 YoY; other operating income was KSEK 2 versus KSEK 0.

• EBITDA was KSEK -8,994 versus -9,624 YoY; EBIT was KSEK -11,547 versus -12,159.

• Net loss was KSEK 11,560 versus KSEK 12,157; EPS was SEK -0.0607 versus -0.0658, and diluted EPS was SEK -0.0585.

• Cash and cash equivalents were KSEK 16,407 at Sept. 30, 2026, versus KSEK 28,550 a year earlier.

Outlook and guidance

• Near-term priorities include completing the Alpha1H Phase III study, pursuing market approval for bladder cancer and developing clinical programs for other indications; commercial progress remains contingent on trial outcomes and approval.

• Plans include a separate study of Alpha1H in severe, therapy-resistant carcinoma in situ at the University of Iowa.

• Anti-infective priorities include extending trials to more severe infections, advancing new compounds into clinical testing and continuing discussions with potential clinical partners.